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Sciences and ChinesAbstract The purpose of this work was to develop a rapid, sensitive and validated HPLC method for
the separation and analysis of a Bromazepam, Medazepam and Midazolam mixture. The three
benzodiazepine compounds were separated on a reversed-phase C18 column at 50 1C using a mobile
phase containing 25% acetonitrile, 45% methanol and 30% ammonium acetate (0.05 M). The pH was
adjusted to pH¼9 by the addition of ammonia solution (35%, w/w). The samples were detected using a
UV detector at 240 nm. The validation study of the method included the effect of temperature, ﬂow rate,
ratio of the components of the mobile phase and the pH of the mobile phase on the efﬁciency of
separation. The linear range of Bromazepam and Midazolam was between 0.12 and 0.18 mg/mL, while
that of Medazepam was between 0.08 and 0.12 mg/mL. The relative standard deviation for precision was
less than 2%. The linearity, selectivity, accuracy and robustness of the developed method showed
acceptable values. The method was applied to the analysis of the samples of raw material of the three
compounds under study, and the percentage of recoveries was 99.89%71.06. It was also applied to the
analysis of samples of pharmaceutical preparations of those compounds and spiked serum samples.
Recoveries from serum samples ranged between 91.5% and 99.0%. The developed method is suitable for
quality control of Bromazepam, Medazepam and Midazolam in their mixtures and in pharmaceutical
preparations (tablets, capsules, ampoules). It can also be used to determine their concentrations in serum.




tute of Materia Medica, Chinese
e Pharmaceutical Association.1. Introduction
Benzodiazepine compounds are used to generate a variety of
pharmacological effects, including anxiolytic, sedative, tran-
quilizer, muscle-relaxant, anti-convulsion or hypnotic (Fig. 1).
The pharmaceutical compounds belonging to this group are
relatively safe when compared with barbiturates as they do not
lead to coma when used in high doses [1]. The inhibitorylsevier B.V. All rights reserved.
Figure 1 General common structure of benzodiazepines.
Figure 2 Structure of the tested compounds Bromazepam,
Medazepam and Midazolam.
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results from its interactions with the GABAA receptors, which
are present in several brain regions [2]. Since medicinal chemist
Strenbach synthesized chlordiazepoxide in 1950, a large
number of benzodiazepine derivatives have been synthesized
and their pharmacological effects have been investigated. At
present, more than twenty of such compounds are globally
marketed for clinical uses [2].
Bromazepam, Medazepam and Midazolam that were under
study in this research (Fig. 2) are among the most important
benzodiazepine derivatives used as anxiolytic, sedative or hyp-
notic drugs, let alone the wide-scale use of Midazolam as a
premedicant medicine before surgery [1,3,4]. These compounds
are the most commonly prescribed class of drugs in the world for
the treatment of anxiety and insomnia, particularly for the elders
[5]. These facts lend importance to the study of the pharmaco-
kinetics and bioavailability of these compounds and their
concentrations in serum in cases of abuse: forensic cases, drug
poisoning or suicidal excessive doses [6–8].
These three components had not been included yet in the
U.S. Pharmacopoeia till its 2010 edition [9]. The analytical
methods described by the British, European and Japanese
Pharmacopoeia in the monographs of the three studied
compounds depend on the anhydrous titration by perchloric
acid in the presence of acetic anhydride, and the end point is
determined by a potentiometer [3,10,11].
Literature reviews have listed a number of publications on
the analysis and determination of therapeutic and toxic blood
concentrations [7] of Bromazepam, Medazepam and Midazo-
lam either as raw materials or in serum [12–14]. But the
analysis of the mixture, as in this research, was not found in
any of these publications [15,16]. These researches have
adopted several methods, including HPLC [15,17–19], LC-
MS [20] and GC-MS [21], in addition to electrochemical and
spectral methods [16,22,23]. The aim of this study was to
develop a valid, rapid and sensitive analytical procedure using
high performance liquid chromatography (HPLC) for the
separation and concentration determination of a mixture of
Bromazepam, Medazepam and Midazolam.2. Experimental
2.1. Materials and methods
Bromazepam, Medazepam and Midazolam as secondary
standard materials were obtained from the Syrian Ministryof Health. The samples of raw materials were purchased
from several local private pharmaceutical factories. The
ﬁnished pharmaceutical samples (tablets, ampoules, cap-
sules) were obtained from the community pharmacy and
from several local and foreign pharmaceutical factories,
including the brand company. Human serum samples were
obtained from a hospital laboratory. Solvents especially for
HPLC (acetonitrile, methanol, water) were purchased from
the Merck, Panreac, Scharlau and Cham Lab companies.
Ammonium acetate (extra pure) was purchased from
Scharlau, ammonia solution (35%, w/w) was purchased
from Surec. Excipient, microcrystalline cellulose (Avicel Ph
102), was purchased from Gujarart Micro Wax. Lactose
crystalline, magnesium stearate and talc were purchased
from Borculo.
2.2. Instruments and equipment
Cecil HPLC chromatographic system provided with Cecil
adept UV/vis detector (CE4200) was used. Two pumps
(CE4100), Cecil adept dual piston pump, with manual
injector (20 mL loop) were used to deliver the mobile phase
to the analytical column in a special oven column
(CE4600); Ce11601 Column oven. Column C18 (3 mm)
(250 mm 4.6 mm) Teknokroma columns TR-013204
Ultrafast Columns Tracer Extrasil was used. An ultrasonic
device, Cole-Parmer-8892, a sensitive balance, Sartorius
analytic balance (CPA225D) (sensitivity of 105 g) and a
pH-meter, Orion model 320 with glass electrode, were also
used. Centrifuge, Hermle Z 230A, and Cartridge 18, RP-
Adsorbex by Merck, Darmstadt. FR were employed for
serum samples.
2.3. Chromatographic conditions
The mobile phase consisted of acetonitrile, methanol, and
0.05 M ammonium acetate (25:45:30, v/v/v). The pH (pH¼9)
was adjusted by adding ammonia solution (35%, w/w). The
H. al-Hawasli et al.486detector wavelength was 240 nm. The ﬂow rate was main-
tained at 1.3 mL/min. The column temperature was set at
50 1C. The injection volume was 20 mL.
2.4. Preparation of solutions
2.4.1. Preparation of stock solutions
Stock solutions of 0.75 mg/mL Bromazepam, 0.50 mg/mL
Medazepam, and 0.75 mg/mL Midazolam were prepared.
375 mg of Bromazepam was weighed and placed in a
500 mL volumetric ﬂask. It was dissolved in an appropriate
amount of the mobile phase solution, and stirred using a
magnetic stirrer for a period between 15–30 min until it was
completely dissolved. The 500 mL volume of the solution was
ﬁlled with the mobile phase to obtain the desired concentra-
tion. Following the same procedure, 250 mg Medazepam and
375 mg Midazolam were weighed to prepare the desired stock
solutions.
2.4.2. Preparation of standards
Standard solutions of 0.15 mg/mL Bromazepam, 0.10 mg/mL
Medazepam, and 0.15 mg/mL Midazolam were prepared by
taking 5 mL stock solution of 0.75 mg/mL Bromazepam
0.50 mg/mL Medazepam, and 0.75 mg/mL Midazolam with
a calibrated pipette and placing them in a 25 mL volumetric
ﬂask. The full volume of the ﬂask was ﬁlled with the mobile
phase to get the desired concentrations.
2.4.3. Preparation of the standard mixture solution of
Bromazepam, Medazepam and Midazolam
5 mL of each of the stock solutions of Bromazepam, Meda-
zepam and Midazolam was transferred to a 25 mL volumetric
ﬂask. The full volume was ﬁlled with the mobile phase, which
was stirred on an ultrasonic device for 15 min to get the
mixture solution of 0.15 mg/mL Bromazepam, 0.10 mg/mL
Medazepam, and 0.15 mg/mL Midazolam.
2.4.4. Preparation of solutions for validation study
2.4.4.1. Standard solutions for linearity study. Five sequential
concentrations were prepared from the stock solution contain-
ing respectively 80%, 90%, 100%, 110% and 120% of the
standard solution concentration. They were prepared by
transferring 8, 9, 10, 11, 12 mL of the stock solution,
respectively, to a 50 mL ﬂask, ﬁlling the full volume of the
ﬂask with the mobile phase, and mixing.
2.4.4.2. Solutions for accuracy study. Tablet excipients [24]
(i.e. Avesel, lactose, talc, magnesium stearate) were spiked to
the standard solutions to obtain analyzed samples. Nine
samples were divided into three groups containing respectively
80%, 100% and 120% of standard solution concentration.
2.4.4.3. Solutions for precision study. Tablet samples were
analyzed. Nine samples were prepared and divided into three
groups containing respectively 80%, 100% and 120% of
standard solution concentration.
2.4.4.4. Solutions for selectivity study. A drug-free sample
was prepared from the excipients (Avesel, lactose, talc,
magnesium stearate). Three tablet samples containing 100%
of standard solution concentration were also analyzed.2.4.4.5. Solutions for robustness study. Three tablet samples
containing 100% of standard solution concentration were
analyzed. The ﬁrst sample was injected after adjusting the
column oven temperature to 48 1C, second to 50 1C and the
third to 52 1C.
2.4.5. Preparation of samples
2.4.5.1. Raw materials. Samples were prepared in the same
way as for the preparation of standard solutions of Broma-
zepam, Medazepam and Midazolam.
2.4.5.2. Tablets. Bromazepam tablet samples were prepared
by weighing 20 tablets individually and the average weight per
tablet was calculated. The tablets were ground to get a ﬁne
powder. The powder equivalent to 30 mg of Bromazepam was
weighed and placed in a 100 mL volumetric ﬂask. The powder
was dissolved with the mobile phase, and mixed on a magnetic
stirrer for half an hour. The full volume of the ﬂask was ﬁlled
with the mobile phase and mixed. The solution was ﬁltered
through Buchner’s funnel with 0.45 mm ﬁlters. 50 mL of the
ﬁltrate was placed into a 100 mL volumetric ﬂask and the full
volume was ﬁlled with the mobile phase to obtain 0.15 mg/mL
solution of Bromazepam. Midazolam sample solutions were
prepared in the same way to obtain a concentration of
0.15 mg/mL. For Medazepam, the powder equivalent to
25 mg of Medazepam was weighed and treated the same
way. 50 mL of the ﬁltrate was placed into a 100 mL volumetric
ﬂask and the full volume was ﬁlled with the mobile phase to
eventually obtain 0.10 mg/mL solution of Medazepam.
2.4.5.3. Capsules. Bromazepam capsule samples were pre-
pared by weighing 20 capsules individually and then calculat-
ing the average weight per capsule. The equivalent of 25 mg of
Bromazepam was weighed from the powder content of the
capsules, which was placed in a 100 mL volumetric ﬂask. The
powder was dissolved with the mobile phase and mixed on a
magnetic stirrer for half an hour. The full volume of the ﬂask
was ﬁlled with the mobile phase and mixed. The solution was
ﬁltered through Buchner’s funnel with 0.45 mm ﬁlters. 60 mL
of the ﬁltrate was placed into a 100 mL volumetric ﬂask and
the full volume was ﬁlled with the mobile phase to obtain
0.15 mg/mL solution of Bromazepam.
2.4.5.4. Ampoules. Midazolam ampoule samples were pre-
pared from (50 mg/10 mL) ampoule solution. The ampoule
solution was mixed for 5 min and 3 mL of the solution was
placed into a 100 mL volumetric ﬂask. The full volume was ﬁlled
with the mobile phase and mixed well to obtain 0.15 mg/mL
solution of Midazolam.
2.4.6. Preparation of a series of standard solutions to
determine the recovery from the serum
A series of standard solutions were prepared in the following
concentrations (12–15–20–25–30 mg/mL) of Bromazepam,
Medazepam and Midazolam by diluting their standard solu-
tions (0.15 mg/mL for both Bromazepam and Midazolam and
0.10 mg/mL for Medazepam).
2.4.7. Preparation of a series of serum standard solutions
The above-mentioned series of standard solutions were pre-
pared with doubled concentrations. Each 1 mL of the solu-
tions was added to 1 mL drug-free serum to obtain a new
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tions of the said series. The serum standard solutions were
centrifuged for half an hour.
2.4.8. Extraction
The serum solution was extracted by the liquid/solid extrac-
tion method using C18 cartridge in the following way:– Precondition cartridge with 3 mL of methanol, withdraw.
Then with 3 mL of water, withdraw.– Apply the serum solution.– Benzodiazepines were eluted with 10 mL of a mixture of
methanol and acetonitrile (1:1). The eluates were left to
dry for 15 min. Dry residues were reconstituted with
mobile phase. The solutions were ﬁltered through
0.45 mm HPLC ﬁlters before injected directly to HPLC.Figure 3 Chromatograms of Bromazepam, Midazolam and
Medazepam using the mixture of acetonitrile, methanol and
0.05 M ammonium acetate (10:57:33, v/v/v) as mobile phase with
a ﬂow rate of 1 mL/min at 25 1C column temperature.2.4.9. Preparation of mobile phase
2.4.9.1. Preparation of 0.05 M ammonium acetate solu-
tion. 3.854 g of anhydrous ammonium acetate (molecular
weight¼77.08 g) was weighed and placed into a 1 L volu-
metric ﬂask. Distilled water was added and the mixture was
stirred until complete dissolution. The full volume of the ﬂask
was ﬁlled with distilled water and the resulting solution was
ﬁltered through 0.45 mm ﬁlters.
2.4.9.2. Preparation of one liter of mobile phase. In 1 L
volumetric ﬂask was added 250 mL acetonitrile, 400 mL
methanol and 300 mL of a fresh solution of 0.05 M ammo-
nium acetate. The ﬂask was ﬁlled with methanol to 1 L and
mixed well. Several drops of ammonia solution (35%, w/w)
was added to adjust pH to 9 under stirring. The resulting
solution was ﬁltered through 0.45 mm ﬁlters.Figure 4 Chromatograms of Bromazepam, Midazolam and
Medazepam using the mixture of acetonitrile, methanol and
0.05 M ammonium acetate (10:57:33, v/v/v) as mobile phase with
a ﬂow rate of 1.3 mL/min at 50 1C column temperature.3. Results
3.1. Method development
3.1.1. Wavelength selection
The ultraviolet spectra [25] of Bromazepam, Medazepam and
Midazolam showed the maximum absorption wavelength at
239 nm for Bromazepam, 253 nm for Medazepam and 220 nm
for Midazolam. Therefore, 240 nm wavelength was selected
after comparing the spectra to achieve the highest sensitivity
for the studied compounds [15].
3.1.2. Selection of mobile phase and experimental conditions
Many different combinations of the mobile phase were tested
until the suitable phase, namely, acetonitrile, methanol,
0.05 M ammonium acetate (10:57:33, v/v/v), was reached.
The obtained chromatogram showed a separation process
and the appearance of three separated peaks representing
Bromazepam, Midazolam and Medazepam (Fig. 3) with
retention times at 5.12, 13.61 and 26.65 min, respectively.
For conﬁrmation, a solution of each compound was injected
separately.
3.1.3. Selection of ﬂow rate and column temperature
Increasing the column temperature from 25 1C to 50 1C led to
a decrease in the total time required for the separationprocess. Also, increasing the ﬂow rate from 1 mL/min to
1.5 mL/min showed a similar decrease in the retention time.
Sufﬁcient ﬂow rate of 1.3 mL/min was chosen to avoid
overlap between peaks and the loss of its acceptable resolu-
tion values (Fig. 4).3.1.4. Ratios of the mobile phase components
We examined the effect of a gradual increase in acetonitrile
from 10% to 25%, which led to a decrease in the total time
required for the separation to 9 min (Fig. 5).
In order to improve the shapes of the peaks and to improve
the separation between Bromazepam and Midazolam, we
improved the previous experimental conditions and started
to change the mobile phase pH using an ammonia solution
(35%, w/w).
H. al-Hawasli et al.4883.1.5. Effect of mobile phase pH
We studied the effect of varying the pH between 7.57 and 9,
using ammonia solution (35%, w/w). We observed that the
best separation results were achieved at pH¼9 (Fig. 6).
3.2. Validation of the method
Identity of each peak was conﬁrmed by the retention time.
Method compatibility with the requirements of system suit-
ability according to the standards of U.S. Pharmacopeia [9]Figure 5 Chromatograms of Bromazepam, Midazolam and
Medazepam using the mixture of acetonitrile, methanol and
0.05 M ammonium acetate (25:45:30, v/v/v) as mobile phase with
a ﬂow rate of 1.3 mL/min at 50 1C column temperature.
Figure 6 Chromatograms of 0.15 mg/mL Bromazepam, 0.15 mg/mL
Midazolam and 0.10 mg/mL Medazepam using mobile phase (25%
acetonitrile, 45% methanol, 30% ammonium acetate 0.05M). pH¼9
was adjusted by adding 35% (w/w) ammonia solution.
Table 1 The most important constitutional standards in the chr
Compound Area Theoretical plates
Bromazepam 19974 3348
Midazolam 14163 5766
Medazepam 12246 5139was performed. Linearity for Bromazepam and Midazolam
covering the range between 0.12 to 0.18 mg/mL and 0.08 to
0.12 mg/mL for Medazepam was veriﬁed. The calibration
curve linearity was examined by studying the correlation
coefﬁcient between the concentrations and the response area
of each concentration.
Accuracy was assessed by the recovery percentage. Relative
standard deviations for selectivity, repeatability, intermediate
precision and robustness were less than 2%. Table 1 features
the most important constitutional standards in the chromato-
gram of a mixture of Bromazepam, Midazolam and Medaze-
pam. Table 2 summarizes the results of the method validation
tests of the three compounds.
3.3. Sample test results
3.3.1. Raw materials
The percentage of active substance in each sample was
calculated from the ratio of the peak areas of sample and
standard solution. The results are shown in Table 3.
3.3.2. Pharmaceutical preparations
Tablet and capsule samples of Bromazepam were analyzed.
The percentage of active substance in each sample was
calculated from the peak areas of samples and standard
solutions. Results of Bromazepam samples are shown in
Table 4.
Tablet and ampoule samples of Midazolam were analyzed.
The percentage of active substance in each sample was also
calculated. Results are shown in Table 5.
Tablet samples of Medazepam were analyzed. The percen-
tage of active substance in each sample was also calculated.
Results are shown in Table 6.
3.3.3. Serum samples
The method was applied to analyze serum samples. Standard
serological solutions were injected using the chromatographic
conditions of our separation method. Linearity was acceptable
in the range of 12–30 mg/mL. Table 7 shows the recovery
results of the serum samples for each concentration after
comparing areas of the standard serological series peaks with
areas of standard solution series peaks. Fig. 7 shows the
chromatogram of a serum sample containing a mixture of
0.025 mg/mL of Bromazepam, Midazolam and Medazepam.4. Discussion
A sensitive, accurate and rapid analytical method has been
developed in this study. It can be used for the analysis and
separation of a mixture of three benzodiazepine compounds;
Bromazepam, Medazepam and Midazolam. The chromato-
graphic conditions were: reversed phase C18 column was usedomatogram of the mixture.




Table 2 Method validation results.











0.985 100.65 98.91 99.76 100.11 101.53 1.20 4.20
Midazolam Y¼84.45X
þ1655
0.994 99.50 99.81 101.09 100.93 100.17 1.02 3.42
Medazepam Y¼115.1X
þ1055
0.994 100.37 99.62 100.64 100.21 100.13 3.03 10.12











Bromazepam A 19920 19984 99.68
Bromazepam B 19846 19984 99.31
Medazepam A 12195 12266 99.42
Medazepam B 12090 12266 98.57
Midazolam A 14377 14193 101.30
Midazolam B 14339 14193 101.03


















1 A tab/6 20391 19958 102.17
2 B tab/6 19734 19958 98.88
3 C cap/1.5 20698 19958 103.71
cap/3 20281 19958 101.62
4 D tab/1.5 21107 19958 105.76
tab/3 20257 19958 101.50
5 E tab/3 22277 19958 111.62
tab/6 20812 19958 104.28


















1 A amp/5 14512 14172 102.40
2 B tab/7.5 14852 14172 104.80
3 C tab/7.5 13789 14172 97.30
tab/15 16387 14172 115.63
4 D tab/7.5 15739 14172 111.06


















1 A tab/10 12187 12285 99.20
2 B tab/5 12584 12285 102.43
tab/10 12480 12285 101.59
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consisted of 25% acetonitrile, 45% methanol and 30% 0.05 M
ammonium acetate; the pH¼9 was adjusted by adding an
ammonia solution (35%, w/w); the ﬂow rate was 1.3 mL/min
and UV detector wavelength was set at 240 nm.
Up to their latest editions, pharmacopoeias (USP 2010 [9],
BP 2009 [3], E.P 2007 [10], JP 2006 [11]) had not yet described
any HPLC method to analyze any of our studied compounds.
International references have adopted many HPLC methods
for the separation and the analysis of several benzodiazepine
mixtures [15,17–19] but our mixture was not found in any of
them. Mobile phases containing one solvent or two did not
achieve the separation of the three compounds. Separationsucceeded when a mixture of acetonitrile, methanol and
0.05 M ammonium acetate (25%:45%:30%) was used [15].
Raising column temperature up to 50 1C at a ﬂow rate of
1.3 mL/min led to a decrease in the retention times of the studied
compounds. The total analysis time was reduced from 30 to
16 min and the peak shapes were also improved. Increasing the
acetonitrile ratio from 10% to 25% reduced the retention times of
the three compounds to a total of 9 min. It also improved the
symmetry of Medazepam and Midazolam peaks.
Raising the mobile phase pH to 9 improved particularly the
symmetry of the three peaks. The tailing factors ranged
between 0.9 and 2.5. Statistically, the symmetry of Midazolam
and Medazepam peaks became acceptable and their tailing
factors were 1.25 and 0.91, respectively. Bromazepam
peak symmetry did not improve much and some tailing
remained. The tailing factor value was 2.53 (Fig. 6, Table 1).
These changes, after raising the mobile phase pH to 9, could
be explained by the transformation of the majority of





1 0.012 95.7 96.6 91.5
2 0.015 94.1 95.9 93.3
3 0.020 97.3 94.4 92.8
4 0.025 98.8 96.0 94.8
5 0.030 99.0 94.8 93.9
Figure 7 Chromatogram of a serum sample containing a mixture
of 0.025 mg/mL of Bromazepam, Midazolam and Medazepam.
H. al-Hawasli et al.490Medazepam (pKa¼6.2) and Midazolam (pKa¼6.2) mole-
cules to non-ionized form, which increased its afﬁnity to the
stationary phase and thus improved peak separation and
symmetry [26]. While for Bromazepam (pKa¼2.9, 11),
pH¼9 transformed the majority of its molecules to ionized
form. This in turn may explain the tailing observed in the
Bromazepam peak.
Nevertheless, values of detection and quantiﬁcation limits
for the three compounds indicate a good sensitivity of the
method. Examined raw material samples were acceptable
according to the pharmacopeia [3,11] for the three studied
compounds; the active substance percentage values ranged
between 98.57% and 101.30%, which is within the pharma-
copeial accepted range (98.5%–101.5%) [3,11]. Examined
pharmaceutical preparation samples of Bromazepam and
Medazepam were pharmacopeially acceptable within the
speciﬁed range (85%–115%) [3]. Four examined Midazolam
samples from ﬁve sources (including a brand company
preparation) were acceptable according to the pharmacopeia
[3]. The recovery percentages of serum samples spiked with
Bromazepam, Medazepam and Midazolam ranged between
91.5% and 99.0%.5. Conclusions
The method described in this study is simple, rapid, sensitive
and accurate for the quantitative determination of three
benzodiazepines: Bromazepam, Medazepam and Midazolam
in pharmaceutical preparations (tablet, capsule and ampoule).It could also be used for the determination of their concentra-
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